GM29369
iPSC from Fibroblast
Description:
TALEN MEDIATED INTEGRATION OF A SINGLE COPY OF TRE3G-HNGN2 AT THE AAVS1 LOCUS AND A SINGLE COPY OF CAG-DCAS9-BFP-KRAB AT THE CLYBL LOCUS OF NCRM-5 IPSC LINE
APPARENTLY HEALTHY INDIVIDUAL
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Gene-Edited hiPSC |
|
License Required
|
For commercial institutions interested in purchasing this iPSC line, additional licensing may be required. Please reach out to our customer service team at customerservice@coriell.org for more information.
|
| Protocols |
Protocol PDF |
|
Cell Type
|
Stem cell
|
|
Cell Subtype
|
Induced pluripotent stem cell
|
|
Transformant
|
Reprogrammed (Episomal)
|
|
Sample Source
|
iPSC from Fibroblast
|
|
Race
|
Unknown
|
|
Country of Origin
|
USA
|
|
Family History
|
N
|
|
Relation to Proband
|
proband
|
|
Confirmation
|
Molecular characterization before cell line submission to CCR
|
|
ISCN
|
46,XY[20]
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| Passage Frozen |
10 |
| |
| Induced Pluripotent Stem Cell |
The frozen cell line submitted to the Repository was recovered and expanded. The expanded line was evaluated for viability surface antigen expression and alkaline phosphatase activity. Pluripotency was assessed via embryoid body (EB) formation. Steady-state mRNA expression patterns of undifferentiated iPSC and EBs were determined via real-time PCR. Characterization data are included in the Certificate of Analysis. |
| |
| Remarks |
This cell line (“Original Material”) contains the Tetracycline controllable expression system (the "Tet Technology") which is covered by a series of patents including U.S. Patent Nos. 8,383,364; 9,181,556; European Patents EP 1954811; 235283 and corresponding patent claims outside these regions proprietary to TET Systems GmbH & Co. KG ("Tet Systems"). The purchaser of the Original Material (“Recipient”) is granted an automatic license to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties.
Researchers purchasing hiPSCs from the NIGMS Repository are responsible for any limited use label licenses (LULLs) applicable to the cell line purchased. The applicable LULL to this line is iPS Academia, Japan Inc.. |
| Baghbaderani BA, Tian X, Neo BH, Burkall A, Dimezzo T, Sierra G, Zeng X, Warren K, Kovarcik DP, Fellner T, Rao MS, cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications Stem cell reports5:647-59 2015 |
| PubMed ID: 26411904 |
| Passage Frozen |
10 |
| Split Ratio |
1:8 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Percent O2 |
AMBIENT |
| Medium |
mTeSR1 |
| Serum |
none |
| Substrate |
Matrigel |
| Supplement |
- |
|
|